Oxaliplatin

For research use only.

Catalog No.S1224 Synonyms: L-OHP

58 publications

Oxaliplatin Chemical Structure

Molecular Weight(MW): 397.29

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 57 In stock
USD 70 In stock
USD 120 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Oxaliplatin has been cited by 58 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution.
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HKESC-2 NEjNfGxEgXSxdH;4bYNqfHliQYPzZZk> NH3WRpox6oDVMU[wxsDPxE1? MU[0POKhcA>? MULJR|UxRTVwONMgxtHDqDBwNTFOwG0> MUKyOlQ4PDZ7Mx?=
CaES-17 NYT0fHFyS3m2b4TvfIlkcXS7IFHzd4F6 NIDCOZcx6oDVMU[wxsDPxE1? NXjVfYQxPDkEoHi= NVHYeolVUUN3ME21MlXDqMLzwrCwMlIh|ryP MXWyOlQ4PDZ7Mx?=
SW480 MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrFVmZvPDhiaNMg M4HMNWlEPTB;MT64O{DPxE1? MojyNlYzPjl5NUm=
HCT116 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDLdZBJPDhiaNMg MnPFTWM2OD1zMT64OkDPxE1? Mk\tNlYzPjl5NUm=
LoVo NHTTPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PoU|Q5KGkEoB?= MkDoTWM2OD17ND64N{DPxE1? NVrSe4I6OjZ{Nkm3OVk>
SK-BR-3 MkH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\yXlJDUUN3ME2zNU4xKMLzIECuNUDPxE1? M3ztd|I3OjFzNUmx
MCF-7 NHXSN5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHy2WXJKSzVyPUG1MlQhyrFiMD6zJO69VQ>? NFi0cHYzPjJzMUW5NS=>
MDA-MB-231 M3LZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f5e2lEPTB;MkOuNUDDuSByLkGg{txO NEfGZ|kzPjJzMUW5NS=>
HCT116 p53+/+ NFvOcmZHfW6ldHnvckBCe3OjeR?= NVrMbnoxOS93IN88US=> MWSyOE81QCCq NXjpcIVrcW6mdXPld{B1emGwc3PybZB1cW:wYXygdoVxemW|c3nvckBw\iCGVWStUi=> MV6yOlIxQDV{Mx?=
LoVo  NVvxflRrTnWwY4Tpc44hSXO|YYm= NXXaXllROS93IN88US=> NGmzU2czPC92ODDo M2iw[4lv\HWlZYOgeJJidnOlcnnweIlwdmGuIILldJJme3Orb36gc4YhTFWWLV6= NETxPJUzPjJyOEWyNy=>
SNU-398 M1XobWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fRWWlEPTB;Nj61xsDDucLiMT6xJO69VQ>? NX\2O29nOjZzNkC0Nlk>
Hep-G2 NITXe4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV75fW1kUUN3ME2xN{4yyqEEsdMgNU43KM7:TR?= MXiyOlE3ODR{OR?=
SNU-475 NXK2VJl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfVTWM2OO,:nkOwJO69VQ>? M{WzSlI3OTZyNEK5
SNU-387 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7KPWNKSzVyPUK1xsDDucLiMj63JO69VQ>? MYWyOlE3ODR{OR?=
HT29 NVnVSWo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XqT2lEPTB;MD64POKhyrIEoECuNkDPxE1? Mnz4NlYyPDh3OU[=
HCT116 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33Re2lEPTB;MD60NeKhyrIEoECuNFIh|ryP MnnnNlYyPDh3OU[=
PA-1 NYX3c3ptS2WubDDWbYFjcWyrdImgRZN{[Xl? NFS3VlIxNTJyIN88US=> NIDidZozPC92ODDo NFfGZVVqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NITQe2ozPjF|OE[3NS=>
OVCAR-5 NWCyZ25kS2WubDDWbYFjcWyrdImgRZN{[Xl? MljRNE03OCEQvF2= MlPkNlQwPDhxN{KgbC=> Mm\2bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MYiyOlE{QDZ5MR?=
SK-OV-3 M2nDfmNmdGxiVnnhZoltcXS7IFHzd4F6 M3u5[FAuOTByIN88US=> NGr6cHczPC92OD:3NkBp NGGyd5RqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MXOyOlE{QDZ5MR?=
PA-1 MX\GeY5kfGmxbjDBd5NigQ>? NEDjWFEyOCEQvF5CpC=> MX6yOIg> NU[2c3d[fHKrZ3fldoV{KHSqZTDwdo9lfWO2aX;uJI9nKHS7cHWgTUBKTk6|IHHu[EBkcGWvb3vpcoV{ MknKNlYyOzh4N{G=
OVCAR-5 NI\3[FZHfW6ldHnvckBCe3OjeR?= M{jjTFMxKM7:TR?= MYe0PIg> M4izeJRzcWepZYLld{B1cGVicILv[JVkfGmxbjDv[kB1gXCnIFmgTWZPeyCjbnSgZ4hmdW:taX7ldy=> NFPL[oMzPjF|OE[3NS=>
SK-OV-3 M2X1fWZ2dmO2aX;uJGF{e2G7 Mnf4OVAh|ryP MkDDPVYhcA>? NVj1fWlLfHKrZ3fldoV{KHSqZTDwdo9lfWO2aX;uJI9nKHS7cHWgTUBKTk6|IHHu[EBkcGWvb3vpcoV{ MXKyOlE{QDZ5MR?=
PA-1 NUPQOWtxTnWwY4Tpc44hSXO|YYm= NHXzXpUyOCEQvF5CpC=> MkXyOFhp M3;0d5VxNXKnZ4XsZZRmeyC2aHWgd5Rz\XO|IHzp[4Fv\HNiZn;yJG5MKGOnbHytZYN1cX[jdHnu[{Bz\WOncITvdpMh[W6mIGTSRWlNKHKnY3XweI9zew>? M3rBflI3OTN6Nkex
OVCAR-5 M2XVbWZ2dmO2aX;uJGF{e2G7 MWGzNEDPxE1? NV\YR4lSPDiq M2naVpVxNXKnZ4XsZZRmeyC2aHWgd5Rz\XO|IHzp[4Fv\HNiZn;yJG5MKGOnbHytZYN1cX[jdHnu[{Bz\WOncITvdpMh[W6mIGTSRWlNKHKnY3XweI9zew>? MV6yOlE{QDZ5MR?=
SK-OV-3 NXH4XnRXTnWwY4Tpc44hSXO|YYm= M2XGO|UxKM7:TR?= MX:5OkBp M3jPUJVxNXKnZ4XsZZRmeyC2aHWgd5Rz\XO|IHzp[4Fv\HNiZn;yJG5MKGOnbHytZYN1cX[jdHnu[{Bz\WOncITvdpMh[W6mIGTSRWlNKHKnY3XweI9zew>? NIjlcXIzPjF|OE[3NS=>
PA-1 NHqxPHZHfW6ldHnvckBCe3OjeR?= M{fsXFExKM7:TdMg MV2yOIg> MmHIdJJwdW:2ZYOgd4Vve2m2aY\peJkhd2Zib4\hdolidiClYYLjbY5wdWFidH:gUmsh[2WubD3t[YRq[XSnZDDjfZRwdHm|aYO= MVKyOlE{QDZ5MR?=
OVCAR-5 NHvv[XZHfW6ldHnvckBCe3OjeR?= NHz6bHgzOCEQvF5CpC=> MoDGNlRp MUXwdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?= M{j2[FI3OTN6Nkex
SK-OV-3 MWfGeY5kfGmxbjDBd5NigQ>? MoPoOVAh|ryPwrC= NUfUS2d{PDhiaNMg MV7wdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?= MWCyOlE{QDZ5MR?=
CT26  Mmm4SpVv[3Srb36gRZN{[Xl? MU[0JI1O NVXlU4dnPDhiaNMg MXrpcoR2[2W|IHH1eI9xcGGpeR?= NIrDXmgzPjF|N{CxNi=>
CT26  MYnGeY5kfGmxbjDBd5NigQ>? M{\2W|QhdU1? NXXaNmtoPDhiaNMg NVi0ZXUzcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuczDv[kBifXSxcHjh[5kuemWuYYTl[EBxem:2ZXnud{whe3WlaDDhd{BNSzNvSVmsJGJm[2yrbkGgZY5lKEGWR{W= NXXLWpp5OjZzM{ewNVI>
CT26  NFvVUYFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NIHhU2c1KG2P MYG0PEBpyqB? MX3k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlidH:gOVMvOiV? MXWyOlE{PzBzMh?=
BE NF7LUWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH6THBKSzVyPUOuN|Mh|ryP NGTrS4MzPjB{M{C4OS=>
Colo205 M1vIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPSXZVbUUN3ME2zMlM{KM7:TR?= NE[3TlczPjB{M{C4OS=>
DLD1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3mRpdKSzVyPUKuNFEh|ryP Mor4NlYxOjNyOEW=
HT29 Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnMdYtDUUN3ME2yMlY6KM7:TR?= NWnLbGVxOjZyMkOwPFU>
HCT15 M{SzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\oTWM2OD1zLkSzJO69VQ>? NWXPZ2RyOjZyMkOwPFU>
HCT116 M{X0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i0cGlEPTB;MT6wOEDPxE1? NYfJV5VEOjZyMkOwPFU>
HCT116p53- NEjJSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7lTWM2OD1zLkC4JO69VQ>? MX:yOlAzOzB6NR?=
KM12 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTRwM{eg{txO MYWyOlAzOzB6NR?=
LoVo MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[0cWlEPTB;MT6yJO69VQ>? MVmyOlAzOzB6NR?=
RKO M2W1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjTWIw1UUN3ME2xMlI{KM7:TR?= NWXrTFM6OjZyMkOwPFU>
SW480 M4rLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LJWmlEPTB;Mj64OkDPxE1? M4[yXlI3ODJ|MEi1
SW620 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm3TWM2OD1|Lk[4JO69VQ>? NUTPflFyOjZyMkOwPFU>
MC38 NEXjXVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIOxboNKSzVyPUKzJO69VSEEsTCy M4j3RVI3ODB2MEi0
HT29 NXv4XFh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELoVI5KSzVyPU[zJO69VSEEsTCxPC=> M3zIWVI3ODB2MEi0
DLD-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[1TWM2OD1|Mj6yJO69VQ>? MVmyOlAxOzB6NR?=
HT-29 NU\lSIp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTN3Lk[g{txO M1z0dVI3ODB|MEi1
SiHa M4S3[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnixTWM2OD1yLkigxtEhOC5zIN88US=> NF\RcZUzPThyMUCwOy=>
S3 NHuyXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfq[ZY3UUN3ME21N{42KMLzIEGuOUDPxE1? Mlr1NlU5ODFyMEe=
AGS NHvmbo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFyyOVNKSzVyPUGwMlYh|ryP M3vsUVI2Pzh7MEW3
MKN-45 NWHsc4pNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fiSmlEPTB;MUSuNEDPxE1? Ml;HNlU4QDlyNUe=
TMK-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7sWYRKSzVyPUKyMlYh|ryP NH\Hd5ozPTd6OUC1Oy=>
SCM-1 Ml3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTF5LkWg{txO MYGyOVc5QTB3Nx?=
HCT-15 M4PDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfsTWM2OD16Lk[0JO69VQ>? MnjyNlU4PjF2N{m=
DiFi MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrPTWM2OD1zMD65OUDPxE1? MmnvNlU4PjF2N{m=
DLD-1 M4\RPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRThwNkWg{txO MXWyOVc3OTR5OR?=
COLO-320DM MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojXTWM2OD13LkO4JO69VQ>? Mn7BNlU4PjF2N{m=
SNU-175 NX\OWFJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PuT2lEPTB;MT61NUDPxE1? MVeyOVc3OTR5OR?=
HT-29 NFzvb49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXK2bGFYUUN3ME21MlIzKM7:TR?= MnrXNlU4PjF2N{m=
SW620 NV7kRVMxTnWwY4Tpc44hSXO|YYm= M2jFNVEx6oDLwsXnM41t NG\tNHEzPOLCiXi= M2L4NIlv[3KnYYPld{BNSzNvSVmgZYNkfW23bHH0bY9vKGGwZDDk[YNz\WG|ZYOgVFYzKGW6cILld5Nqd25? MUWyOVc1QTR{MB?=
SW480 NVSzPIhXTnWwY4Tpc44hSXO|YYm= NGXGSnoyOOLCidM1[{9udA>? NX[2ZnhDOjUkgJno MV;pcoNz\WG|ZYOgUGM{NUmLIHHjZ5VufWyjdHnvckBidmRiZHXjdoVie2W|IGC2NkBmgHC{ZYPzbY9v MX2yOVc1QTR{MB?=
SW620 M1[wTWZ2dmO2aX;uJGF{e2G7 NGTwVXUyOOLCidM1[{9udA>? MmO5NlTjiImq MYnlcohidmOnczDj[YxtfWyjcjDheZRweGijZ3njJIZtfXh? NYXHbIJXOjV5NEm0NlA>
SW480 MlTiSpVv[3Srb36gRZN{[Xl? M{HRVlEx6oDLwsXnM41t NGD1TZozPOLCiXi= MYXlcohidmOnczDj[YxtfWyjcjDheZRweGijZ3njJIZtfXh? MUOyOVc1QTR{MB?=
A549 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTVwODFCtUAxNjZizszN MYGyOVYzPTJ2Mx?=
A549/CDDP NVnJc3E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjpTWM2OD1zOD62JOKyKDFwMjFOwG0> M4jTNVI2PjJ3MkSz
Panc-1 NVSzT|h1S2WubDDWbYFjcWyrdImgRZN{[Xl? M1jh[FI2NzVyIN88US=> MXuyOE81QCCq NV7MPFR3cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDv[kBRSyClZXzsd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD MlT6NlU1PDR7MUS=
MIAPaCa-2 M{GyT2NmdGxiVnnhZoltcXS7IFHzd4F6 MWiyOU82OCEQvF2= NFn6UpozPC92ODDo MmfXbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC MU[yOVQ1PDlzNB?=
SW1990 M3zTVWNmdGxiVnnhZoltcXS7IFHzd4F6 NFTzV4YzPS93MDFOwG0> MV6yOE81QCCq NFqyWoxqdmirYnn0d{Bxem:uaX\ldoF1cW:wIH;mJHBEKGOnbHzzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? MkP0NlU1PDR7MUS=
HPDE NUPQe4pQS2WubDDWbYFjcWyrdImgRZN{[Xl? NHzsd4czPS93MDFOwG0> MYSyOE81QCCq MVrpcohq[mm2czDwdo9tcW[ncnH0bY9vKG:oIGDDJINmdGy|IHnuJIEhe3mwZYLnbZN1cWNibXHucoVzKGOxbXLpcoVlKHerdHigW2E> NWntNnhyOjV2NES5NVQ>
Panc-1 MnrPRZBweHSxc3nzJGF{e2G7 MmXXNlXjiIoEtV2= NX;jc2dtOjRiaB?= MYHpcoR2[2W|IHHwc5B1d3OrczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC M3K0[FI2PDR2OUG0
MIAPaCa-2 M4DqTmFxd3C2b4Ppd{BCe3OjeR?= M{P6Z|I26oDLwsXN M2DQXVI1KGh? NHK1PZBqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIIP5coVz\2m|dHnjJI1idm6ncjDjc41jcW6nZDD3bZRpKFeD M{nvW|I2PDR2OUG0
Panc-1 MYDGeY5kfGmxbjDBd5NigQ>? MkLKNlXjiIoEtV2= NF24bXozPC92ODDo NXziblNJcW6mdXPld{BkdGWjdnHn[UBw\iCSQWLQMEBk[XOyYYPlMVktKGOjc4Dhd4UuQCCjbnSgZ4F{eGG|ZT2zxsA> NV;l[JBCOjV2NES5NVQ>
MIAPaCa-2 MYHGeY5kfGmxbjDBd5NigQ>? MnjTNlXjiIoEtV2= NIC1ZZkzPC92ODDo M1LmeYlv\HWlZYOgZ4xm[X[jZ3Wgc4YhWEGUUDygZ4F{eGG|ZT25MEBk[XOyYYPlMVgh[W6mIHPhd5Bie2VvM9Mg NFnrbnkzPTR2NEmxOC=>
SW480 NX60VYQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn20O|IhcMLi MlHqTWM2OD1zMD63xtEzNjJ4INM1[{9uVA>? MYiyOVM3ODZ|MR?=
HCT116  NWLLeY9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:5PJh7PzJiaNMg M1zvWGlEPTB;Nj6yN:KyOC55NTFCuYcwdUx? MVuyOVM3ODZ|MR?=
COC1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnDR|BVUUN3ME20Ok4zOMLiwsJCpFMvOTRizszN MWCyOVMxPzR2OB?=
SGC7901 NHi5eGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTjTmRvUUN3ME2yNU44O8LiwsJCpFMvODhizszN NXXGb5pOOjV|MEe0OFg>
A549 NVXPT2w6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTVzLkC4xsDDucLiMUCuPVYh|ryP NFXaO|AzPTNyN{S0PC=>
HepG2 NInu[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7C[ZpKSzVyPUG0MlI1yqEEsdMgNU45OiEQvF2= MoDjNlU{ODd2NEi=
MCF-7 M1[2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4iy[GlEPTB;MUSuNlTDqMLzwrCxMlgzKM7:TR?= NGLhb|EzPTNyN{S0PC=>
HCT-116 NHT1VINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTZwMkVCpOKyyqB{Lkm3JO69VQ>? NH3zc4ozPTNyN{S0PC=>
HT-29 M1r2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzaRW5KSzVyPkWwJO69VQ>? NEnHWlEzPTNyN{S0PC=>
HEK293 NIfkbY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe4Opo3UUN3ME24MlgzyqEEsdMgOU42QSEQvF2= M2rsZlI2OzB5NES4
HUVEC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH0UYlKSzVyPUGxMlMxyqEEsdMgNU4xOiEQvF2= MXuyOVMxPzR2OB?=
SW480 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmxxsDPxE1? NV3ZNFFuOC15MjDo MmOybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> M1j6e|I1QTl5NEWx
HT-29 NI\v[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlznNeKh|ryP NGTsTlExNTd{IHi= MkTxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MWiyOFk6PzR3MR?=
HCT116 MW\GeY5kfGmxbjDBd5NigQ>? M4HyUVIwPSEEtV2= M335SVI1NzR6IHi= NUPadHB{e3WycILld5NmeyC|dYL2bZZqdiCvUl7BJIV5eHKnc4Ppc44> MVuyOFc3OTRzMR?=
SW480  MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonsOFghcMLi MknpTWM2OD1{MD64JJVoN22O M1TVNVI1PzJyNke1
SW620 MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PNd|ExNTdyIH3nM2w> Ml:0NlQwPDhxN{KgbC=> NF:0dI9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M2jB[VI1PjR4M{C1
Caco2  NVr6S2FNTnWwY4Tpc44hSXO|YYm= NICxTWw{OMLizszN M3zBO|I1KGh? MYHEUXNQ NXjHUIRWcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBJVy1zLDDBT3IySyxiYX7kJG5SVzF? NU\G[XJwOjR3NU[0NVU>
Caco2  NV7q[W9MTnWwY4Tpc44hSXO|YYm= M4ryRlMwOTBxM{Cg{txO Ml[wNVYhcA>? NWD1dJp[TE2VTx?= MWnpcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBCU1JzQ{GsJG5SVzFuIFjPMVEtKE2UUEKsxsBidmSPUmCzxsBld3OnLXTldIVv\GWwdHz5 M37vTVI1PTV4NEG1
Caco2 MlXRSpVv[3Srb36gRZN{[Xl? MX[zNE8yODEEoN88US=> M1PqO|E3yqCq NEXESJBFVVOR MnO3ZYN1cX[jdHXzJG5z\jJ? MVOyOFU2PjRzNR?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
VEGFR-1 / NRP-1 ; 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin (0.2 and 2 μmol/L) in 1% MEM-FBS. Western blotting analysis showed that oxaliplatin treatment up-regulated VEGFR-1 and NRP-1 protein expression. 

p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416); 

PubMed: 18790786     


HT29 cells were treated with oxaliplatin for 5, 15, 30, and 60 min. Western blotting showed that oxaliplatin induced Akt activation, with peak phosphorylation occurring at 60 min and decreased PTEN. Phospho-Src increased at 30 min.

p-Src(Y418) / p-FAK(Y861) ; 

PubMed: 19383922     


Src and FAK activation by Western blots were determined at various time periods after oxaliplatin treatment (2.5 µM) for HT29 and KM12-L4 cells, and representative of triplicate experiments. Densitometry represents a ratio of the phosphorylated form to th䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ

18790786 19383922
Immunofluorescence
E-cadherin / Vimentin; 

PubMed: 30787271     


Silencing ATXN2L reversed oxaliplatin-induced epithelial mesenchymal transition in MGC803 cells.

ATXN2L / G3BP1; 

PubMed: 30787271     


Under different concentrations and durations of oxaliplatin stimulation, the immunfluorescence staining expressions of ATXN2L and G3BP1 were enhanced by different levels, and ATXN2L coexpressed with G3BP1 in stress granules. 

30787271
Growth inhibition assay
Cell viability ; 

PubMed: 28339092     


Cell viability curve of BGC-823 and MKN-28 cells treated with oxaliplatin at different concentrations. 

28339092
In vivo A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol

Cell Research:[4]
- Collapse
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method: The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control
    (Only for Reference)
Animal Research:[6]
- Collapse
  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro Water 3 mg/mL warmed (7.55 mM)
Ethanol 0.01 mg/mL (0.02 mM)
DMF Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% glucose (with warming)
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage powder
temperature in solvent (should be freshly prepared each time)
Synonyms L-OHP
Smiles [Pt++].NC1CCCCC1N.[O-]C(=O)C([O-])=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04158349 Not yet recruiting Drug: Oxaliplatin|Drug: mFOLFIRI Colorectal Cancer|Appendiceal Cancer|Peritoneal Carcinoma University of Utah May 2020 Phase 1
NCT04003792 Not yet recruiting Drug: oxaliplatin|Drug: FOLFIRI Protocol|Drug: Bevacizumab Liver Metastasis Colon Cancer Rabin Medical Center January 2020 Phase 2
NCT04261920 Recruiting Drug: Huangqi Guizhi Wuwu decoction Oncology Jiangsu Famous Medical Technology Co. Ltd. January 3 2020 Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • Answer:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Oxaliplatin | Oxaliplatin supplier | purchase Oxaliplatin | Oxaliplatin cost | Oxaliplatin manufacturer | order Oxaliplatin | Oxaliplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID